correspondence
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
To the Editor:
Since the first marketing approvals of recombinant biopharmaceuticals, the question of which changes in quality
attributes, which comprise identity, strength and purity, are acceptable in the life cycle .
d

eof these products without changing the vrproduct label has been debated extensively1esThis question is especially important in the . er context of manufacturing process changes, sthwhich happen quite frequently and for
givarious reasons (e.g., process improvements, r lscale changes or site transfers). Although l Acompanies and health authorities have been .cnmanaging these quality changes for many I ,years based on the principle that changes in acquality attributes can be accepted only if they iredo not alter safety and efficacy, the lack of mpeer-reviewed data in the public domain has Aelimited debates about product quality and rutvariation to a discussion of principles rather aNthan specifics. Here, we present a study that 11looks at variation in three major marketed 02biologics, the purpose of which is to provide ©more transparency and to anchor the debate about acceptable changes in quality attributes on a firmer factual footing. Identifying such variations in quality attributes could help not only biotech companies in their development efforts but also the medical and scientific communities in understanding these
products. By analyzing the quality profiles of the glycosylated recombinant therapeutic proteins Aranesp (darbepoetin alfa), Rituxan/Mabthera (rituximab) and Enbrel (etanercept) sourced from the market between 2007 and 2010, our data thus provide examples of acceptable variations for products that have remained on the market with unchanged product labels.
molecules and even a well-controlled Glycosylated proteins are complex product may consist of several hundred or more glycoforms having the same amino acid sequence but different glycan composition. When making these products, the manufacturer has to deliver a consistent product quality to guarantee a reproducible
310
clinical performance. Current analytical methods allow the detection of even small attributes have no adverse impact upon safety changes in quality attributes and can therefore or efficacy of the drug product.”
enable sensitive monitoring of the batch-to-batch consistency and variability of the make and require the complete assessment of Comparability decisions are difficult to manufacturing process. Several different the existing process and product including the factors may account for changes in quality knowledge of structure-function relationships. attributes. The first is the inherent batch-Others1to-batch variability in the manufacturing collection of data would be extremely valuable have already acknowledged that a process. Second, process drifts can lead to to come to a more informed design and
gradual changes of attributes. Such drifting improved assessment of comparability studies. events are not desired and normally trigger And yet, very little data on commercialized further investigations and corrective actions, products can be found in the public domain. or even redevelopment activities to ensure In an attempt to at least partially fill this gap, process consistency. Finally, larger and
we have analyzed multiple batches of Aranesp, abrupt changes in quality attributes can occur Rituxan/Mabthera and Enbrel to study the after implementation of manufacturing variability in the quality attributes of modern process changes, which are all too common therapeutic proteins currently on the market. in the pharmaceutical industry. Although The data were generated as described in the manufacturers try to prevent associated Supplementary Methodschanges in quality attributes, such changes listed in Supplementary Tables 1, using the materials and 2.cannot be avoided in every case.
of Aranesp, darbepoetin alfa, is an The active pharmaceutical ingredient process are tightly regulated by the health Changes in the biologics manufacturing erythropoiesis-stimulating protein. It
authorities. Manufacturers need to
represents an engineered analog of human demonstrate that the process change does erythropoietin. It differs from endogenous not alter the clinical safety or efficacy of the erythropoietin mainly by an alteration of the biologic product. The evaluation of such amino acid sequence that introduces two changes follows a comparability exercise additional between the pre- and post-change product, in an elongated half-life N-glycosylation sites, which results which is focused on the quality level and activity and clinical effect of erythropoietins in vivo. The biological sometimes, depending on the magnitude is influenced by the glycosylation profile, of the change and the existing product which needs to be tightly controlled during understanding, also requires comparative production2data on the preclinical and clinical levels. The principles of the comparability exercise batches sourced in the European Union (EU) We have characterized commercial
.
are regulated in guidelines, such as the
by capillary zone electrophoresis, which International Conference on Harmonisation separates isoforms with different charges (ICH) Q5E (doc.guandang.net from varying numbers of sialic acids Public_Web_Site/ICH_Products/Guidelines/per molecule (Quality/Q5E/Step4/Q5E_Guideline.pdf), Fig. 1Fig. 1 which acknowledges that “the demonstration known to be dependent on the number ). The in vivo biological activity is and Supplementary of comparability does not necessarily mean of sialic acid units per molecule, which is that the quality attributes of the pre-change a result of the available sialylation sites, and post-change product are identical, but the antennarity of the that they are highly similar and that the completeness of sialylationN-glycans and the 3existing knowledge is sufficiently predictive to ensure that any differences in quality span a range from November 2008 to April The expiry dates of the tested batches .
2011. We found a change of the isoform
volume 29 number 4 april 2011 nature biotechnology
et al.: Acceptable changes in quality attributes of glycosylated biopharmaceuticals Nature Biotechnology 29, 310-312, 2011 11
glycosylated biopharmaceuticals 1982-1985 1985 - 2005 mAbs & Etanercept The low productivity of cell culture started the trend to build extremely costly, ...
for complex biopharmaceuticals and most are N-glycosylated at an Asparagine. ...In contrast, intact moss plants (protonema) are grown in simple media of ...
for complex biopharmaceuticals and most are N-glycosylated at an Asparagine. ...In contrast, intact moss plants (protonema) are grown in simple media of ...
热门文档